See more : Chongqing Qin’an M&E PLC. (603758.SS) Income Statement Analysis – Financial Results
Complete financial analysis of PharmaCielo Ltd. (PCLO.V) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PharmaCielo Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Sequans Communications S.A. (SQNS) Income Statement Analysis – Financial Results
- Zhongfu Information Inc. (300659.SZ) Income Statement Analysis – Financial Results
- Acosta Verde, S.A.B. de C.V. (GAVA.MX) Income Statement Analysis – Financial Results
- Kobayashi Yoko Co., Ltd. (8742.T) Income Statement Analysis – Financial Results
- WH Smith PLC (SMWH.L) Income Statement Analysis – Financial Results
PharmaCielo Ltd. (PCLO.V)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.pharmacielo.com
About PharmaCielo Ltd.
PharmaCielo Ltd., together with its subsidiary, cultivates, processes, produces, and supplies medicinal-grade cannabis extracts, tetrahydrocannabinol, and related products. The company also offers telemedicine software. It serves health and wellness product manufacturers, pharmacies, medical clinics, and cosmetic companies in Canada and Colombia. The company has a strategic alliance with AssuredTrans Inc. PharmaCielo Ltd. is headquartered in Toronto, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.54M | 5.31M | 1.94M | 2.65M | 786.90K | 0.00 | 0.00 |
| Cost of Revenue | 2.91M | 4.48M | 6.25M | 9.45M | 2.45M | 653.63K | 0.00 |
| Gross Profit | -1.37M | 827.06K | -4.31M | -6.80M | -1.66M | -653.63K | 0.00 |
| Gross Profit Ratio | -88.78% | 15.58% | -221.51% | -256.19% | -210.90% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 7.81M | 10.70M | 17.94M | 31.21M | 29.63M | 118.61K | 0.00 |
| Selling & Marketing | 411.96K | 779.19K | 1.08M | 1.13M | 900.66K | 0.00 | 0.00 |
| SG&A | 8.33M | 11.48M | 19.01M | 32.34M | 30.53M | 118.61K | 15.98K |
| Other Expenses | 0.00 | 778.66K | 1.87M | 4.28M | 2.14M | -25.79K | 0.00 |
| Operating Expenses | 8.33M | 12.26M | 20.89M | 36.62M | 32.67M | 118.61K | 15.98K |
| Cost & Expenses | 11.24M | 16.74M | 27.14M | 46.07M | 35.12M | 118.61K | 15.98K |
| Interest Income | 176.00 | 1.83K | 2.37K | 65.58K | 585.13K | 0.00 | 0.00 |
| Interest Expense | 2.86M | 1.54M | 561.29K | 272.73K | 173.84K | 25.79K | 0.00 |
| Depreciation & Amortization | 1.41M | 1.58M | 1.32M | 1.48M | 1.28M | 653.63K | 0.00 |
| EBITDA | -12.02M | -10.50M | -24.84M | -41.55M | -33.21M | -23.76M | -15.98K |
| EBITDA Ratio | -779.54% | -186.12% | -1,244.64% | -1,565.79% | -4,153.31% | 0.00% | 0.00% |
| Operating Income | -9.70M | -11.46M | -25.46M | -43.12M | -33.96M | -118.61K | -15.98K |
| Operating Income Ratio | -629.22% | -215.87% | -1,309.24% | -1,624.81% | -4,316.11% | 0.00% | 0.00% |
| Total Other Income/Expenses | -6.60M | -3.89M | -2.89M | -3.38M | -703.86K | 6.46M | 0.00 |
| Income Before Tax | -16.30M | -14.52M | -26.63M | -43.76M | -34.67M | -144.40K | -15.98K |
| Income Before Tax Ratio | -1,057.09% | -273.45% | -1,369.14% | -1,648.73% | -4,405.55% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.52M | 288.00K | 504.42K | -44.88K | 25.79K | 0.00 |
| Net Income | -16.30M | -16.04M | -26.92M | -44.26M | -34.62M | -144.40K | -15.98K |
| Net Income Ratio | -1,057.09% | -302.11% | -1,383.94% | -1,667.73% | -4,399.85% | 0.00% | 0.00% |
| EPS | -0.10 | -0.11 | -0.18 | -0.39 | -0.36 | -1.18 | -0.04 |
| EPS Diluted | -0.10 | -0.11 | -0.18 | -0.39 | -0.36 | -1.18 | -0.04 |
| Weighted Avg Shares Out | 160.08M | 150.98M | 145.64M | 112.54M | 96.05M | 122.19K | 388.61K |
| Weighted Avg Shares Out (Dil) | 160.08M | 150.98M | 145.64M | 112.54M | 96.05M | 122.19K | 388.61K |
Source: https://incomestatements.info
Category: Stock Reports